Blair William & Co. IL Sells 16,942 Shares of Sarepta Therapeutics, Inc. $SRPT

Blair William & Co. IL cut its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 38.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 27,173 shares of the biotechnology company’s stock after selling 16,942 shares during the period. Blair William & Co. IL’s holdings in Sarepta Therapeutics were worth $465,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also bought and sold shares of the business. State of Alaska Department of Revenue increased its position in Sarepta Therapeutics by 2.6% during the first quarter. State of Alaska Department of Revenue now owns 11,175 shares of the biotechnology company’s stock worth $713,000 after acquiring an additional 285 shares during the period. State of Michigan Retirement System increased its position in Sarepta Therapeutics by 1.3% during the first quarter. State of Michigan Retirement System now owns 22,900 shares of the biotechnology company’s stock worth $1,461,000 after acquiring an additional 300 shares during the period. Louisiana State Employees Retirement System increased its holdings in Sarepta Therapeutics by 1.1% in the 1st quarter. Louisiana State Employees Retirement System now owns 26,800 shares of the biotechnology company’s stock valued at $1,710,000 after buying an additional 300 shares during the period. Ancora Advisors LLC increased its holdings in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares during the period. Finally, Cambridge Investment Research Advisors Inc. increased its holdings in Sarepta Therapeutics by 5.9% in the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 6,387 shares of the biotechnology company’s stock valued at $408,000 after buying an additional 358 shares during the period. 86.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on SRPT. Royal Bank Of Canada raised their target price on shares of Sarepta Therapeutics from $14.00 to $16.00 and gave the company a “sector perform” rating in a report on Wednesday, October 8th. Guggenheim reissued a “buy” rating and issued a $22.00 target price on shares of Sarepta Therapeutics in a report on Monday, September 15th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Sarepta Therapeutics to $12.00 and gave the company a “sell” rating in a report on Friday, August 15th. Jefferies Financial Group decreased their target price on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Thursday, July 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Sarepta Therapeutics in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and seven have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $34.42.

Sarepta Therapeutics Stock Down 3.6%

Shares of NASDAQ SRPT opened at $22.51 on Friday. The company has a market capitalization of $2.20 billion, a P/E ratio of -25.87 and a beta of 0.51. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $138.81. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The company’s 50 day moving average price is $19.61 and its 200-day moving average price is $29.44.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $1.13. The firm had revenue of $611.09 million for the quarter, compared to the consensus estimate of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company’s revenue for the quarter was up 68.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.07 EPS. Equities analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.